204 related articles for article (PubMed ID: 33860208)
21. Neuronal nicotinic receptor agonists ameliorate spontaneous motor asymmetries and motor discoordination in a unilateral mouse model of Parkinson's disease.
Kucinski A; Wersinger S; Stachowiak EK; Corso TD; Parry MJ; Zhang J; Jordan K; Letchworth S; Bencherif M; Stachowiak MK
Pharmacol Biochem Behav; 2013 Oct; 111():1-10. PubMed ID: 23872135
[TBL] [Abstract][Full Text] [Related]
22. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model.
Zhang L; Zhang L; Li L; Hölscher C
Neuropeptides; 2018 Oct; 71():70-80. PubMed ID: 30017231
[TBL] [Abstract][Full Text] [Related]
23. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
Jalewa J; Sharma MK; Gengler S; Hölscher C
Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
[TBL] [Abstract][Full Text] [Related]
24. Striatal dopamine transmission is subtly modified in human A53Tα-synuclein overexpressing mice.
Platt NJ; Gispert S; Auburger G; Cragg SJ
PLoS One; 2012; 7(5):e36397. PubMed ID: 22570709
[TBL] [Abstract][Full Text] [Related]
25. MitoPark transgenic mouse model recapitulates the gastrointestinal dysfunction and gut-microbiome changes of Parkinson's disease.
Ghaisas S; Langley MR; Palanisamy BN; Dutta S; Narayanaswamy K; Plummer PJ; Sarkar S; Ay M; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
Neurotoxicology; 2019 Dec; 75():186-199. PubMed ID: 31505196
[TBL] [Abstract][Full Text] [Related]
26. Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice.
Gellhaar S; Marcellino D; Abrams MB; Galter D
Genes Brain Behav; 2015 Mar; 14(3):260-70. PubMed ID: 25752644
[TBL] [Abstract][Full Text] [Related]
27. Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent.
Jensen ME; Galli A; Thomsen M; Jensen KL; Thomsen GK; Klausen MK; Vilsbøll T; Christensen MB; Holst JJ; Owens A; Robertson S; Daws L; Zanella D; Gether U; Knudsen GM; Fink-Jensen A
Neurochem Int; 2020 Sep; 138():104772. PubMed ID: 32464226
[TBL] [Abstract][Full Text] [Related]
28. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.
Cao L; Li D; Feng P; Li L; Xue GF; Li G; Hölscher C
Neuroreport; 2016 Apr; 27(6):384-91. PubMed ID: 26918675
[TBL] [Abstract][Full Text] [Related]
29. Altered glutamate release in the dorsal striatum of the MitoPark mouse model of Parkinson's disease.
Farrand AQ; Gregory RA; Bäckman CM; Helke KL; Boger HA
Brain Res; 2016 Nov; 1651():88-94. PubMed ID: 27659966
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Harkavyi A; Abuirmeileh A; Lever R; Kingsbury AE; Biggs CS; Whitton PS
J Neuroinflammation; 2008 May; 5():19. PubMed ID: 18492290
[TBL] [Abstract][Full Text] [Related]
31. Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson's Disease Mouse Model.
Zhang Z; Hao L; Shi M; Yu Z; Shao S; Yuan Y; Zhang Z; Hölscher C
J Parkinsons Dis; 2021; 11(2):529-543. PubMed ID: 33523018
[TBL] [Abstract][Full Text] [Related]
32. The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons.
Wang Y; Bouabid S; Darvas M; Zhou FM
Exp Neurol; 2020 Nov; 333():113427. PubMed ID: 32735872
[TBL] [Abstract][Full Text] [Related]
33. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
[TBL] [Abstract][Full Text] [Related]
34. Probiotics Alleviate the Progressive Deterioration of Motor Functions in a Mouse Model of Parkinson's Disease.
Hsieh TH; Kuo CW; Hsieh KH; Shieh MJ; Peng CW; Chen YC; Chang YL; Huang YZ; Chen CC; Chang PK; Chen KY; Chen HY
Brain Sci; 2020 Apr; 10(4):. PubMed ID: 32244769
[TBL] [Abstract][Full Text] [Related]
35. Imaging in Parkinson's disease: the role of monoamines in behavior.
Brooks DJ; Piccini P
Biol Psychiatry; 2006 May; 59(10):908-18. PubMed ID: 16581032
[TBL] [Abstract][Full Text] [Related]
36. MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348.
Grauer SM; Hodgson R; Hyde LA
Psychopharmacology (Berl); 2014 Apr; 231(7):1325-37. PubMed ID: 24150248
[TBL] [Abstract][Full Text] [Related]
37. Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice.
Langley M; Ghosh A; Charli A; Sarkar S; Ay M; Luo J; Zielonka J; Brenza T; Bennett B; Jin H; Ghaisas S; Schlichtmann B; Kim D; Anantharam V; Kanthasamy A; Narasimhan B; Kalyanaraman B; Kanthasamy AG
Antioxid Redox Signal; 2017 Nov; 27(14):1048-1066. PubMed ID: 28375739
[TBL] [Abstract][Full Text] [Related]
38. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Garau A; Carboni E; Carta AR
Neurotox Res; 2009 Aug; 16(2):127-39. PubMed ID: 19526289
[TBL] [Abstract][Full Text] [Related]
39. Regenerative effects of peptide nanofibers in an experimental model of Parkinson's disease.
Sever M; Turkyilmaz M; Sevinc C; Cakir A; Ocalan B; Cansev M; Guler MO; Tekinay AB
Acta Biomater; 2016 Dec; 46():79-90. PubMed ID: 27619838
[TBL] [Abstract][Full Text] [Related]
40. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
Wakamatsu M; Iwata S; Funakoshi T; Yoshimoto M
J Neurosci Res; 2008 Feb; 86(3):640-6. PubMed ID: 17896793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
